Search clinical trials for: AZD2014

Total 110 results

Samsung Medical Center

Withdrawn

Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy (TSC1/2_SC)

Solid Tumor

Korea, Republic of
Massachusetts General Hospital
United States Department of Defense; AstraZeneca

Completed

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Meningioma | Neurofibromatosis 2

United States
Massachusetts General Hospital
National Cancer Institute (NCI); AstraZeneca

Active, not recruiting

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Meningioma

United States
Samsung Medical Center
AstraZeneca

Terminated

Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification ([SUKSES-D])

Small Cell Lung Cancer

Korea, Republic of
Samsung Medical Center

Withdrawn

Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy (RICTOR_SC)

Solid Tumor

Korea, Republic of
AstraZeneca

Withdrawn

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (INHIBITOR)

Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
Royal Marsden NHS Foundation Trust
AstraZeneca; Institute of Cancer Research, United Kingdom

Completed

A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel. (TAX-TORC)

Advanced Cancer

United Kingdom
Canadian Cancer Trials Group
AstraZeneca

Completed

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Glioblastoma Multiforme

Canada
AstraZeneca

Active, not recruiting

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca

Completed

Study to Investigate the Pharmacodynamic Effect of a Single Dose of AZD2516 in Healthy Male Subjects

Reflux

Netherlands, Belgium
Samsung Medical Center

Terminated

Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy

Cancer of Stomach

Korea, Republic of
Samsung Medical Center

Terminated

Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy (AZD2014)

Stomach Neoplasms

Korea, Republic of
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca

Completed

Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer (CaNCaP02)

Prostate Cancer

United Kingdom
AstraZeneca

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

Advanced Solid Malignancies

United Kingdom
Samsung Medical Center
AstraZeneca

Terminated

AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3]

Small Cell Lung Cancer

Korea, Republic of
Queen Mary University of London
AstraZeneca; Cancer Research UK

Unknown

A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers (TORCMEK)

Squamous Cell Lung Cancer | Triple-Negative Breast Cancer | Non-squamous Cell Lung Cancer With KRAS Mutations | Non-squamous Cell Lung Cancer With Wild-type KRAS

United Kingdom
AstraZeneca

Completed

Bioavailability of AZD0284 and IV Microtracer Study

Plaque Psoriasis Vulgaris

United Kingdom
AstraZeneca

Completed

A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.

Advanced Solid Tumours

United States
Entasis Therapeutics

Completed

AZD0914 Phase 1 ADME Study in Healthy Volunteers

Healthy

United States
AstraZeneca

Completed

An Open Label Positron Emission Tomography (PET) Study to Determine Central mGluR5 Receptor Occupancy of AZD2516

Healthy

Sweden
AstraZeneca

Completed

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

Healthy

United States
AstraZeneca
National Institutes of Health (NIH); Eolas Therapeutics INC.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers

Smoking Cessation

United States
AstraZeneca
Quintiles, Inc.

Completed

To Investigate the Safety, Tolerability and Pharmacokinetics of AZD2516 After Multiple Dosing in Healthy Volunteers

Part A Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 Years. | Part B Healthy Young Males and Non-fertile Female Volunteers Aged 20 to 45 and Elderly Volunteers Aged 60 to 80

United Kingdom
AstraZeneca

Completed

Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

Obesity

Sweden
AstraZeneca

Completed

Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses (MAD)

Diabetes Mellitus Type 2

Sweden
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017

Healthy

Sweden
Samsung Medical Center

Completed

Study of AZD6094 (Volitinib) in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Third-line Treatment

Advanced Gastric Adenocarcinoma

Korea, Republic of
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.

Healthy

Japan
AstraZeneca

Terminated

Single Ascending Dose Study With Healthy Male Volunteers and Type II Diabetic Patients

Type 2 Diabetes

Sweden
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Dose of AZD2516 to Japanese Healthy Subjects

Healthy

Japan
AstraZeneca

Completed

AZD2624 Multiple Ascending Dose Study in Japan (JMAD)

Healthy | Safety

Japan
AstraZeneca

Terminated

Study to Determine if AZD0284 is Effective and Safe in Treating Plaque Psoriasis (DERMIS)

Plaque Psoriasis Vulgaris

Denmark
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [11C]AZ12713580 to Determine Central mGluR5 Receptor Occupancy of AZD2066 (PET)

Healthy

Sweden
AstraZeneca

Completed

An Open Label Prostate Cancer Study in Japanese Patients

Prostate Cancer

Japan
AstraZeneca
SCRI Development Innovations, LLC

Completed

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Papillary Renal Cell Cancer

United States, Canada, United Kingdom, Spain
Acerta Pharma BV

Terminated

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

DLBCL | Richter Syndrome

United Kingdom, United States
AstraZeneca

Completed

Open Label Prostate Cancer Study

Prostate Cancer

United Kingdom, Netherlands, United States
AstraZeneca

Completed

Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid (PET)

Alzheimer's Disease

Sweden
AstraZeneca
Quintiles, Inc.

Completed

Absorption, Metabolism, Excretion and Pharmacokinetics of a Single Dose [14C]AZD2014 Followed by a Multiple Dose Phase (14C)

Solid Malignancies

United Kingdom
Queen Mary University of London
AstraZeneca; Cancer Research UK

Terminated

A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer (ZEBRA)

Metastatic Clear Cell Renal Carcinoma

United Kingdom
AstraZeneca
Quintiles, Inc.

Terminated

AZD2066 Neuropathic Pain - Mechanical Hypersensitivity (NP-MH)

Neuropathic Pain | Mechanical Hypersensitivity

United States
AstraZeneca

Completed

AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers

Healthy
National Cancer Institute (NCI)

Terminated

Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer

Colorectal Carcinoma | Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage... and other conditions

United States
AstraZeneca

Completed

Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066

Pain

United Kingdom
AstraZeneca
Parexel

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects

Plaque Psoriasis Vulgaris

United Kingdom
AstraZeneca

Completed

AZD2115 Single Ascending Dose Study

Chronic Obstructive Pulmonary Disease | Lung Disease Causing Persistent Narrowing of the Airways

United Kingdom
AstraZeneca

Completed

Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

Pain | Diabetic Neuropathy

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Study to Evaluate the Safety, Tolerability and Plasma PK of a Single Oral Dose of Zoliflodacin in Healthy Male and Female Volunteers

Gonorrhoea

United States
AstraZeneca

Completed

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2066 in Young and Elderly Healthy Subjects

Pain

Sweden
AstraZeneca

Completed

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers

Healthy

Sweden

3

Subscribe